Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : launches review into safety of eye drug Beovu

share with twitter share with LinkedIn share with facebook
share via e-mail
02/25/2020 | 06:37am EDT

Novartis has launched an external review into the safety of its blindness medicine Beovu after the American Society of Retinal Specialists (ASRS) raised concerns.

The Swiss drugmaker's shares fell nearly 3% in early trading after the ASRS communicated to its members about the drug, a replacement for Novartis' blockbuster Lucentis.

Since Beovu's approval last October, ASRS has received reports of 14 cases of vasculitis, an inflammation of the blood vessels, of which 11 were designated occlusive retinal vasculitis - a sight-threatening inflammatory eye condition.

Novartis said it was aware of recently reported adverse effects of the drug, adding it "stands behind the safety and efficacy of Beovu."

"In addition to our own internal assessment, we have engaged an external safety review committee (SRC) to further evaluate these post-marketing cases. We will continue to share details as they become available," the company said.

Around 46,000 injections of Beovu have so far been administered, Novartis said. The U.S. Food and Drug Administration was aware of the review, while the company is now informing other health authorities.

"Our clinical development and pharmacovigilance teams are working with healthcare professionals to quickly obtain and evaluate all available information in order to classify these events and identify potential risk factors," Novartis said.

The company received approval from the FDA for Beovu in October and the go-ahead in Europe earlier this month.

Beovu injections are used to treat wet age-related macular degeneration, a condition which can eventually lead to blindness and affects around 20 million people worldwide.

(Reporting by John Revill; editing by Jason Neely, Kirsten Donovan)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
03/26NOVARTIS : ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Clai..
03/25NOVARTIS : AveXis - Zolgensma data shows rapid, significant, clinically meaningf..
03/24NOVARTIS : Sandoz acquires US distribution rights to two key hospital injectable..
03/23NOVARTIS : Sandoz Gets U.S. Distribution Rights for Two Hospital-Injectable Medi..
03/23NOVARTIS : commits to donate up to 130 million doses of hydroxychloroquine to su..
03/20NOVARTIS : to Donate Drug in Coronavirus Fight
03/20NOVARTIS : receives approval from Japanese Ministry of Health, Labour and Welfar..
03/19NCLAT Affirms That The De Minimis Exemption Should Have Always Applied To The..
03/17NOVARTIS : Joins R&D Efforts, Sets Up $20 Million Fund to Combat Coronavirus
03/13NOVARTIS : secures alternate options for Kymriah shipments after Europe travel b..
More news
Financials (USD)
Sales 2020 50 040 M
EBIT 2020 14 984 M
Net income 2020 9 396 M
Debt 2020 19 663 M
Yield 2020 3,89%
P/E ratio 2020 19,0x
P/E ratio 2021 16,4x
EV / Sales2020 4,01x
EV / Sales2021 3,70x
Capitalization 181 B
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 101,26  $
Last Close Price 79,88  $
Spread / Highest target 57,0%
Spread / Average Target 26,8%
Spread / Lowest Target -7,40%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-17.30%180 007
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
PFIZER, INC.-21.13%171 422
NOVO NORDISK A/S-0.69%133 274